Evidence map›Paper›PMID 25875328›Full record

ArticlePloS one2015

Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy.

Matthew R Sapio, Monique Vessaz, Pierre Thomas, Pierre Genton, Lloyd D Fricker, Annick Salzmann

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Ethanol feeding accelerates pancreatitis progression inAmerican journal of physiology. Gastrointestinal and liver physiology · 2020
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Matthew R SapioDepartment of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, United States of America.
Monique VessazDepartment of Genetic Medicine and Laboratory, University Hospitals of Geneva, Geneva, Switzerland.
Pierre ThomasDepartment of Neurology, University Hospital, Nice, France.
Pierre GentonCentre Saint Paul, Hôpital Henri Gastaut, Marseille, France.
Lloyd D FrickerDepartment of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, United States of America; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, United States of America.
Annick SalzmannDepartment of Psychiatry, University of Geneva, Geneva, Switzerland.
Albert Einstein College of Medicine · USCentre Hospitalier Universitaire de Nice · FRHenri Gastaut Hospital · FRUniversity Hospital of Geneva · CHUniversity of Geneva · CH

Funding

REGULATION OF ENKEPHALIN CONVERTASE--CARBOXYPEPTIDASE ER01DA004494 · NIDA · YESHIVA UNIVERSITY · PI FRICKER, LLOYD D · 1987 to 2015
$5.9M
NIDA NIH HHS 1R01 DA-004494NIDA NIH HHS R01 DA004494
6 · The paper itself

Abstract

Carboxypeptidase A6 (CPA6) is a peptidase that removes C-terminal hydrophobic amino acids from peptides and proteins. The CPA6 gene is expressed in the brains of humans and animals, with high levels of expression during development. It is translated with a prodomain (as proCPA6), which is removed before secretion. The active form of CPA6 binds tightly to the extracellular matrix (ECM) where it is thought to function in the processing of peptides and proteins. Mutations in the CPA6 gene have been identified in patients with temporal lobe epilepsy and febrile seizures. In the present study, we screened for CPA6 mutations in patients with juvenile myoclonic epilepsy and identified two novel missense mutations: Arg36His and Asn271Ser. Patients harboring these mutations also presented with generalized epilepsy. Neither of the novel mutations was found in a control population. Asn271 is highly conserved in CPA6 and other related metallocarboxypeptidases. Arg36 is present in the prodomain and is not highly conserved. To assess structural consequences of the amino acid substitutions, both mutants were modeled within the predicted structure of the enzyme. To examine the effects of these mutations on enzyme expression and activity, we expressed the mutated enzymes in human embryonic kidney 293T cells. These analyses revealed that Asn271Ser abolished enzymatic activity, while Arg36His led to a ~50% reduction in CPA6 levels in the ECM. Pulse-chase using radio-labeled amino acids was performed to follow secretion. Newly-synthesized CPA6 appeared in the ECM with peak levels between 2-8 hours. There was no major difference in time course between wild-type and mutant forms, although the amount of radiolabeled CPA6 in the ECM was lower for the mutants. Our experiments demonstrate that these mutations in CPA6 are deleterious and provide further evidence for the involvement of CPA6 mutations in the predisposition for several types of epilepsy.

Indexed as

MutationAdolescentAdultAllelesAmino Acid SequenceAmino Acid SubstitutionAnticonvulsantsCarboxypeptidases ACase-Control StudiesChildChild, PreschoolDNA Mutational AnalysisEpilepsy, GeneralizedFemaleGene ExpressionGenetic Association StudiesAnticonvulsantsCarboxypeptidases ACPA6 protein, human

Identifiers

PMID25875328
PMCPMC4395397
OpenAlexW2325345587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.